Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Teva Announces Exclusive Launch of Generic Pataday in the United States

By Teva Pharmaceutical Industries | June 9, 2017

Teva Pharmaceutical Industries Ltd. today announced the launch of generic Pataday1 (olopatadine hydrochloride ophthalmic solution) 0.2%, in the U.S.

Olopatadine hydrochloride ophthalmic solution 0.2% is a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis.

With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market. Currently, one in six generic prescriptions dispensed in the U.S. is filled with a Teva product.

“Olopatadine hydrochloride ophthalmic solution 0.2% is an important treatment for our patients and a key addition to our generics product portfolio,” said Dipankar Bhattacharjee, Teva’s president and CEO, Global Generic Medicines. “This launch marks another successful first-to-file product for Teva, bringing the only generic version of this product on the market.”

Pataday had annual sales of approximately $303 million in the U.S., according to IMS data as of March 2017.
_____________________________________________________

Reference:

1 Pataday® is a registered trademark of Alcon Laboratories, Inc., a Novartis company.

(Source: Business Wire)

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards